60 related articles for article (PubMed ID: 22226627)
1. Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis.
Cromwell I; van der Hoek K; Malfair Taylor SC; Melosky B; Peacock S
Lung Cancer; 2012 Jun; 76(3):472-7. PubMed ID: 22226627
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of erlotinib in advanced non-small cell lung cancer: impact on the budget of a U.S. health insurance plan.
Ramsey SD; Clarke L; Kamath TV; Lubeck D
J Manag Care Pharm; 2006; 12(6):472-8. PubMed ID: 16925455
[TBL] [Abstract][Full Text] [Related]
3. Proposal for a novel methodology to screen and score cost versus survival for anticancer drugs in metastatic disease: could cost weigh in evaluation?
Guirgis HM
J Oncol Pract; 2012 Jul; 8(4):224-30. PubMed ID: 23180986
[TBL] [Abstract][Full Text] [Related]
4. Evolution of Diagnoses, Survival, and Costs of Oncological Medical Treatment for Non-Small-Cell Lung Cancer over 20 Years in Osona, Catalonia.
Parera Roig M; Colomé DC; Colomer GB; Sardo EG; Tournour MA; Fernández SG; Ominetti AI; Juvanteny EP; Polo JLM; Jobal DB; Espejo-Herrera N
Curr Oncol; 2024 Apr; 31(4):2145-2157. PubMed ID: 38668062
[TBL] [Abstract][Full Text] [Related]
5. Receipt of financial assistance for oral targeted therapy among older adults with advanced non-small cell lung cancer: A prospective cohort study.
Kumar A; Ragavan M; Velazquez AI; Zeng S; Wong ML
J Geriatr Oncol; 2024 Jun; 15(5):101746. PubMed ID: 38490915
[No Abstract] [Full Text] [Related]
6. Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504).
Chouaid C; Le Caer H; Locher C; Dujon C; Thomas P; Auliac JB; Monnet I; Vergnenegre A;
BMC Cancer; 2012 Jul; 12():301. PubMed ID: 22817667
[TBL] [Abstract][Full Text] [Related]
7. Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective.
Thongprasert S; Tinmanee S; Permsuwan U
Asia Pac J Clin Oncol; 2012 Mar; 8(1):53-61. PubMed ID: 22369444
[TBL] [Abstract][Full Text] [Related]
8. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
[TBL] [Abstract][Full Text] [Related]
9. Cost of combined modality interventions for stage III non-small-cell lung cancer.
Evans WK; Will BP; Berthelot JM; Earle CC
J Clin Oncol; 1997 Sep; 15(9):3038-48. PubMed ID: 9294466
[TBL] [Abstract][Full Text] [Related]
10. Targeted erlotinib for first-line treatment of advanced non-small cell lung cancer: a budget impact analysis.
Bajaj PS; Veenstra DL; Goertz HP; Carlson JJ
J Med Econ; 2014 Aug; 17(8):538-46. PubMed ID: 24716717
[TBL] [Abstract][Full Text] [Related]
11. A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
Jäkel A; Plested M; Dharamshi K; Modha R; Bridge S; Johns A
Appl Health Econ Health Policy; 2013 Feb; 11(1):27-43. PubMed ID: 23329379
[TBL] [Abstract][Full Text] [Related]
12. Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe.
Walleser S; Ray J; Bischoff H; Vergnenègre A; Rosery H; Chouaid C; Heigener D; de Castro Carpeño J; Tiseo M; Walzer S
Clinicoecon Outcomes Res; 2012; 4():269-75. PubMed ID: 23028234
[TBL] [Abstract][Full Text] [Related]
13. Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer.
Vergnenègre A; Ray JA; Chouaid C; Grossi F; Bischoff HG; Heigener DF; Walzer S
Clinicoecon Outcomes Res; 2012; 4():31-7. PubMed ID: 22347803
[TBL] [Abstract][Full Text] [Related]
14. Real-World Cost-Effectiveness Analysis: How Much Uncertainty Is in the Results?
Barr HK; Guggenbickler AM; Hoch JS; Dewa CS
Curr Oncol; 2023 Apr; 30(4):4078-4093. PubMed ID: 37185423
[TBL] [Abstract][Full Text] [Related]
15. Rapid Review of Real-World Cost-Effectiveness Analyses of Cancer Interventions in Canada.
Guggenbickler AM; Barr HK; Hoch JS; Dewa CS
Curr Oncol; 2022 Sep; 29(10):7285-7304. PubMed ID: 36290851
[TBL] [Abstract][Full Text] [Related]
16. The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer.
Ezeife DA; Spackman E; Juergens RA; Laskin JJ; Agulnik JS; Hao D; Laurie SA; Law JH; Le LW; Kiedrowski LA; Melosky B; Shepherd FA; Cohen V; Wheatley-Price P; Vandermeer R; Li JJ; Fernandes R; Shokoohi A; Lanman RB; Leighl NB
Ther Adv Med Oncol; 2022; 14():17588359221112696. PubMed ID: 35923926
[TBL] [Abstract][Full Text] [Related]
17. Economic Evaluations Informed Exclusively by Real World Data: A Systematic Review.
Parody-Rúa E; Rubio-Valera M; Guevara-Cuellar C; Gómez-Lumbreras A; Casajuana-Closas M; Carbonell-Duacastella C; Aznar-Lou I
Int J Environ Res Public Health; 2020 Feb; 17(4):. PubMed ID: 32059593
[TBL] [Abstract][Full Text] [Related]
18. A Systematic Review of Economic Evaluations Assessing the Cost-Effectiveness of Licensed Drugs Used for Previously Treated Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) Negative Advanced/Metastatic Non-Small Cell Lung Cancer.
Gallacher D; Auguste P; Royle P; Mistry H; Armoiry X
Clin Drug Investig; 2019 Dec; 39(12):1153-1174. PubMed ID: 31583605
[TBL] [Abstract][Full Text] [Related]
19. An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis.
Franklin M; Lomas J; Walker S; Young T
Pharmacoeconomics; 2019 May; 37(5):631-643. PubMed ID: 30746613
[TBL] [Abstract][Full Text] [Related]
20. Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature.
Albaba H; Lim C; Leighl NB
Pharmacoeconomics; 2017 Dec; 35(12):1195-1209. PubMed ID: 28861770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
